Paper - WANFANG MED ONLINE

You Position: Home > Paper

Significance of Th17/Treg balance in pathogenesis and treatment of hepatocellular carcinoma

( views:26, downloads:0 )

Author:: No author available

Journal Title:: World Chinese Journal of Digestology

Issue:: 30

DOI:: 10.11569/wcjd.v24.i30.4151

Key Word:: Th17细胞;调节性T细胞;肝细胞肝癌;治疗;T helper 17 cells;Regulatory T cells;Hepatocellular carcinoma;Therapy

Abstract：肝细胞癌是我国常见的恶性肿瘤之一,具有恶性程度高、发展快、易转移等特点.当前治疗方法主要有肝移植、手术切除和局部消融治疗.然而,对于除移植外的所有治疗中,5年后肿瘤复发率高达70％.近几年来,由于常规治疗效果不满意,肝癌的免疫治疗逐渐成为热点.但是肝癌存在严重的肿瘤免疫微环境抑制,影响了肝癌免疫治疗效果.Th17细胞、调节性T细胞(regulatory T cell,Treg)是近年来新发现的CD4+T细胞亚群,在一定条件下,两者存在相互转化的关系,在维持人体自身免疫稳定和抗肿瘤免疫过程中起着重要作用,他们是形成肝癌微环境免疫抑制的重要成员.以Th17或Treg为靶点的肝癌免疫治疗具有潜在可行性,更多证据表明,Thl7/Treg的平衡、失衡机制将为肝癌的免疫治疗提供新的策略.

Reference

[1]徐匹夫,余后火.重组人血管内皮抑素介入栓塞治疗对肝癌恶性生物学行为的影响[J].2015,(6).
[2]曾文,郑晨.T reg、T H17相关细胞因子与原发性肝癌预后的关系[J].2014,(10).
[3]杜国盛,周林,朱志东,等.Foxp3+调节性T细胞与肝癌肝移植患者术后肿瘤复发关系的研究[J].2015,(5).
[4]林秀清,黄智铭,王剑虹,等.CD4+CD25+FoxP3+调节性T细胞在小鼠H22原位肝癌模型中的表达和意义[J].2013,(10).
[5]张增光,秦鸣放.肝癌患者外周血 Treg、Th17百分比及 IL-17水平观察[J].2015,(15).
[6]崇杨,江涛,王轩.原发性肝癌患者射频消融后外周血CD4+CD25+Foxp3+Treg细胞对预后的影响[J].2013,(3).
[7]Bignone PA,Banham AH.FOXP3+ regulatory T cells as biomarkers in human malignancies.[J].2008,8(12).
[8]Pengyuan Yang,Geoffrey J.Markowitz,Xiao-Fan Wang.The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma[J].2014,(3).
[9]Colding Jorgensen M,Bro R,Rasmussen MA,etc.Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma.[J].2010,69(4).
[10]Souza,J.M.,Matias,B.F.,Rodrigues,C.M.,etc.IL-17 and IL-22 serum cytokine levels in patients with squamous intraepithelial lesion and invasive cervical carcinoma[J].2013,34(5).
[11]Zhu,H.,Xu,H.,Su,Z.,etc.Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis[J].2014,58(1).
[12]Zhang,J.,Lao,X.,Chang,A.E.,etc.Interleukin-6 inhibits regulatory t cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells[J].2012,35(4).
[13]荚卫东.根治性肝切除联合索拉非尼治疗肝细胞癌的研究进展[J].2012,(22).
[14]Wang L,Yi T,Kortylewski M.IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway.[J].2009,206(7).
[15]Ayten, Nalbant,Doga, Eskier.Genes associated with T helper 17 cell differentiation and function.[J].2016,(Spec ).
[16]Takeuchi, Yoshiko,Nishikawa, Hiroyoshi.Roles of regulatory T cells in cancer immunity[J].2016,28(8).
[17]Mangia,A.,Patruno,R.,Ranieri,G.,etc.Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: From discovery to clinical development[J].2012,19(7).
[18]Wei Liao,Warren J. Leonard,Peng Li,etc.Complex interactions of transcription factors in mediating cytokine biology in T cells[J].2014,261.
[19]Kolls J,Zou W,Szeliga W,etc.Cutting Edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment.[J].2007,178(11).
[20]Damotte D,Cremer I,Sautes Fridman C,etc.Tumor microenvironment is multifaceted.[J].2011,30(1).
[21]Revathi, Shanmugasundaram,Ramesh K, Selvaraj.In ovo injection of anti-chicken CD25 monoclonal antibodies depletes CD4+CD25+ T cells in chickens.[J].2013,92(1).
[22]Alakananda, Dasgupta,Renu, Saxena.Regulatory T cells: a review.[J].1900,25(6).
[23]Misra SK,Tighe MP,Hamada H,etc.Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.[J].2010,184(8).
[24]Gao, Hanchao,Qian, Youcun,Song, Xinyang.Th17 Differentiation and Their Pro-inflammation Function[J].2014,841.
[25]Shao-Xin, Yao,Gui-Song, Zhang,Hong-Xia, Cao,etc.Correlation between microRNA-21 and expression of Th17 and Treg cells in microenvironment of rats with hepatocellular carcinoma.[J].2015,8(9).
[26]Andrew J. Rech.Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells[J].2009,1174.
[27]Van Veldhuizen PJ,Hashmi MH.Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.[J].2010,10(5).
[28]Emily R, Mercadante,Ulrike M, Lorenz.Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.[J].2016.
[29]Spanoudakis E,Nakou E,Kotoula V,etc.Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes.[J].2011,139(3).
[30]贾士杰,范慧敏,刘伟,等.2002~2011年中国恶性肿瘤死亡率水平及变化趋势[J].2014,(12).